Blog
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
…
17th Dec 2025
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
…
17th Dec 2025
Ivuxolimab: Redefining Cancer Immunotherapy and Research
Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
…
1st Feb 2025
Dupilumab: Transforming Immunotherapy and Skin Disease Management
What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
…
1st Feb 2025
Inebilizumab: Advancing Research and Clinical Applications
What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
…
1st Feb 2025
Naratuximab: Redefining Cancer Therapy with Precision Medicine
Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
…
1st Feb 2025
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research
Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
…
31st Jan 2025
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy
What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
…
31st Jan 2025
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting
Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
…
31st Jan 2025
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment
Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
…
30th Jan 2025
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research
Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
…
29th Jan 2025
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances
What You Need to Know About DenosumabWhat is Denosumab?Denosumab is a monoclonal antibody used primarily to treat osteoporosis and bone-related complications in cancer patients. It targe
…
29th Jan 2025
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research
Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
…
29th Jan 2025
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights
Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
…
29th Jan 2025
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances
Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
…
29th Jan 2025
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research
Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
…
29th Jan 2025
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond
Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
…
29th Jan 2025
Adalimumab: Mechanism, Clinical Applications, and the Role of Biosimilars
Quick Facts About AdalimumabWhat is Adalimumab?Adalimumab is a fully human monoclonal antibody designed to neutralize tumor necrosis factor-alpha (TNF-α), a key cytokine involved in infl
…
29th Jan 2025
Cetuximab: A Revolutionary Drug in Cancer Therapy
Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wo
…
29th Jan 2025
Utomilumab: Advancing Immuno-Oncology Research
Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
…
29th Jan 2025
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics
What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
…
29th Jan 2025
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies
Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
…
29th Jan 2025
Enapotamab: Advancing Cancer Research with Innovative Therapeutics
Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
…
29th Jan 2025
Fezakinumab: Exploring Its Mechanism and Clinical Potential
Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
…
29th Jan 2025